Skip to main content

Table 3 Data of effect modification for continuous clinical outcomes

From: Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? – A systematic review

Outcome Study Genotype N (ACE) Baseline Follow up Mean (SD) ACE inhibitor N (Control) Baseline Follow up Mean (SD) Control group Mean difference (estimated SD) Overall effect (weighted mean and SD)
Reduction in ACE activity (U/I)            
Van Geel [22] DD 8 31† 25† 6.29
(11.20)
12 27† 35† -7.82
(11.22)
14.11
(11.2)
9.84
(0.83)
  DI 23 25.5† 22† 3.14
(10.31)
20 23† 20† -6.76
(10.28)
9.9
(10.3)
 
  II 11 18† 13† 4.61
(7.73)
12 18† 20† -1.42
(3.98))
6.03
(6.1)
 
Reduction in end-systolic blood pressure (mmHg)            
Perna [24] DD 42 147.8
(19.1)
139.8
(15.1)
8.8
(14.58)
45 146
(17.7)
142.8
(13.9)
3.2
(10.68)
5.6
(12.8)
3.1
(12.8)
  DI 47 145.1
(18.9)
139
(17.5)
6.1
(13.88)
52 146.5
(17.2)
143.2
(12.72)
3.3
(12.45)
2.8
(13.08)
 
  II 16 145.1
(18.4)
139.7
(17.8)
5.4
(11.29)
10 153.2
(15.9)
144
(14.7)
9.2
(11.75)
-3.8
(11.85)
 
Reduction in end-diastolic blood pressure (mmHg)            
Perna [24] DD 42 89.9
(11)
86.2
(6.9)
3.8
(8.76)
45 88.6
(10.2)
87.4
(7.6)
1.2
(6.42)
2.6
(7.8)
1.4
(9.1)
  DI 47 88.9
(13.9)
86.1
(9.64)
2.8
(12.10)
52 90.6
(12.6)
88.6
(8.86)
2.0
(9.7)
0.8
(10.9)
 
  II 16 90.8
(11.6)
85.3
(5.8)
4.9
(7.61)
10 97.5
(6.1)
92.1
(6.25)
5.4
(5.67)
-0.5
(7.0)
 
Reduction of proteinuria (g/24 h)            
Perna [24] DD 42 2.85
(1.69)
2.28
(1.5)
0.57
(1.18)
45 2.8
(1.7)
2.73
(1.4)
0.07
(1.10)
0.5
(1.1)
0.33
(1.2)
  DI 47 3.3
(2.2)
2.97
(1.97)
0.51
(1.31)
52 3.8
(2.5)
3.65
(1.9)
0.15
(1.20)
0.36
(1.2)
 
  II 16 3.45
(2.37)
3.41
(3.3)
0.05
(1.57)
10 3.4
(1.7)
3.08
(0.32)
0.32
(1.15)
-0.37
(1.4)
 
Decline of glomerular filtration rate (per months)            
Perna [24] DD 42 44.2
(19.1)
n.a. -0.28
(0.46)
45 40.2
(17)
n.a. -0.43
(0.63)
0.15
(0.54)
0.08
(0.63)
  DI 47 45.3
(20.7)
n.a. -0.48
(0.83)
52 40.6
(17.1)
n.a. -0.52
(0.68)
0.04
(0.75)
 
  II 16 47.3
(23.5)
n.a. -0.38
(0.41)
10 47.8
(20.5)
n.a. -0.37
(0.53)
-0.01
(0.43)
 
Albumin excretion rate(μg/min)            
Penno [23] DD 71 8.1* 17.1† 9.00† 66 8.1* 17.2† 9.78† -0.78 -7.33
  DI 154 7.6* 17.4† 9.80† 142 7.6* 19.1† 11.5† -1.70  
  II 29 9.2* 16.2† 7.00† 48 9.2* 24.3† 15.11† -8.11  
Net gain (mm)            
Okamura [21] DD 9 0.64
(0.27)
1.09
(0.66))
0.45
(0.23)
7 0.49
(0.27)
1.64
(0.96)
1.16
(0.26)
-0.71
(0.2)
0.03
(0.28)
  DI 13 0.58
(0.32)
1.62
(0.79)
1.04
(0.24)
13 0.53
(0.18)
1.42
(0.97)
0.89
(0.26)
0.15
(0.3)
 
  II 10 0.55
(0.25)
1.82
(0.69)
1.27
(0.21)
26 0.65
(0.16)
1.42
(0.54)
0.77
(0.18)
0.5
(0.2)
 
Late Loss (mm)            
Okamura [21] DD 9 2.43
(0.54)
1.09
(0.66))
1.34
(0.23)
7 2.46
(0.57)
1.64
(0.96)
0.82
(0.24)
-0.52
(0.67)
0.15
(0.74)
  DI 13 2.58
(0.55)
1.62
(0.79)
0.96
(0.21)
13 2.32
(0.49)
1.42
(0.97)
0.90
(0.23)
-0.06
(0.79)
 
  I24I 10 2.44
(0.51)
1.82
(0.69)
0.62
(0.16)
26 2.65
(0.25)
1.42
(0.54)
1.23
(0.16)
0.61
(0.75)
 
Loss index (% at follow up)            
Okamura [21] DD 9 n.a. n.a. 0.78
(0.13)
7 n.a. n.a. 0.42
(0.12)
-0.36
(0.36)
0.03
(0.39)
  DI 13 n.a. n.a. 0.53
(0.12)
13 n.a. n.a. 0.49
(0.13)
-0.04
(0.45)
 
  II 10 n.a. n.a. 0.38
(0.09)
26 n.a. n.a. 0.63
(0.08)
0.25
(0.37)
 
Diameter stenosis            
Okamura [21] DD 9 n.a. n.a. 57.4
(23.4)
7 n.a. n.a. 40.08
(26.4)
-0.17
(0.25)
0.03
(0.39)
  DI 13 n.a. n.a. 43.8
(25.2)
13 n.a. n.a. 45.1
(33.9)
0.01
(0.30)
 
  II 10 n.a. n.a. 34.3
(19.9)
26 n.a. n.a. 48.2
(30.6)
0.14
(0.28)
 
  1. Values are presented as means and SD; n.a.: not available; * indicates combined baseline data for intervention and control group; † indicates extracted values of figures (no SD)